Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergey Olegovich Bachurin has a total of 249 co-authors. Here are the top co-authors by number of shared publications:

  • Galina F. Makhaeva

    Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry Russian Academy of Sciences Chernogolovka Russia

    13 shared publications
  • Elena Feofanovna Shevtsova

    Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS), Severny proezd 1, Chernogolovka 142432, Russia

    11 shared publications
  • Nadezhda V. Kovaleva

    Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry Russian Academy of Sciences Chernogolovka Russia

    11 shared publications
  • Alexey Yuryevich Aksinenko

    Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS), Severny proezd 1, Chernogolovka 142432, Russia

    10 shared publications
  • Elena V. Rudakova

    Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry Russian Academy of Sciences Chernogolovka Russia

    10 shared publications
  • Natalia P. Boltneva

    Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry Russian Academy of Sciences Chernogolovka Russia

    10 shared publications

Latest Publications

  • Open Access

    QSAR and Free–Wilson Analysis of Bioisosteric Derivatives of Dimebon to Optimize the Search for Potential Inhibitors of Mitochondrial Permeability Transition

    by Ivan M. Veselov, Denis V. Zverev, Dmitry A. Shulga, Alexey Yu. Aksinenko, Elena R. Milaeva, Vladimir P. Fisenko, Elena F. Shevtsova, Sergey O. Bachurin

    Mitochondrial permeability transition pore (MPTp) opening is a critical event in neurodegeneration, representing a point of no return in cell death cascades. Despite the neuroprotective potential of MPTp inhibitors, systematic structure–activity relationship (SAR) studies for this target remain scarce. Here we present the first standardized dataset of 57 γ-carboline derivatives evaluated for their ability to inhibit MPTp under uniform experimental conditions. Using complementary Free–Wilson and 2D-QSAR analyses, we expertly propose rational structure–activity relationships (SAR) for this scaffold. Based on the Free–Wilson analysis, we assume that increasing lipophilicity and steric bulk at all four substitution positions to a certain limit positively correlates with inhibitory activity. The R3 linker plays a critical role: the presence of positively ionizable amine groups and potentially hydrogen bond donors enhances activity, whereas non-ionizable amide linkers may be detrimental. The QSAR model based on physicochemical descriptors of substituents corroborates these findings, with positive contributions from cLogP and HBD descriptors. This integrated computational–experimental approach provides a predictive framework for the rational design of novel neuroprotective agents targeting MPTp, with potential implications for the treatment of neurodegenerative diseases.

  • Fluorinated Gamma-carboline Derivatives as Promising Neuroprotective Candidates. Structure-Activity Relationships

    by Maria A. Lapshina, Elena F. Shevtsova, German L. Perlovich, Alexey A. Ustyugov, Alexey Y. Aksinenko, Daria V. Vinogradova, Vladimir P. Fisenko, Tatyana V. Volkova, Olga R. Simonova, Maria N. Zakharova, et al.

    Introduction: The structure-property relationship of drug candidates determines their transport to target organs and is used as a tool to design drugs with optimal properties and minimal undesirable effects. The effects of fluorinated derivatives of gamma-carboline on the formation of cytosolic aggregates of the FUS protein and the relationships among structure, physicochemical characteristics, and anti-aggregation properties were studied. Methods: The effect of the compounds on FUS protein aggregation in SH-SY5Y cells was evaluated using confocal fluorescence microscopy. Partition coefficients were determined using the isothermal saturation method, and all descriptors were calculated with a software package. Results: A series of fluorinated γ‑carboline derivatives was synthesized and demonstrated the ability to reduce pathological FUS protein aggregation in a cellular model of proteinopathy. The influence of substituents on the distribution coefficients of the studied compounds was revealed. Among the most active compounds, this study highlights DF-302 and DF-402, which feature a methyl group and a trifluoromethyl group on the pyridinium fragment, respectively. Discussion: The structure-activity relationships for the inhibition of FUS protein aggregation by fluorinated γ-carbolines were analyzed in relation to their physicochemical properties. A linear correlation was observed between the anti-aggregation efficacy and the total hydrogen bond acceptor capacity: as the compound's propensity to form hydrogen bonds with the FUS protein increased, its ability to prevent large aggregate formation in cells decreased. An assumption has been made that off-target interactions of the studied compounds with membrane proteins increase with their hydrogen bond acceptor capacity. This effect can limit compounds' availability to influence the processes of cytosolic FUS protein aggregates. Conclusion: The positive correlation of lipophilicity with FUS aggregate reduction underscores the role of cellular penetration in the anti-aggregation effect. Conversely, the negative correlation with hydrogen-bond acceptor capacity suggests that off-target interactions with membrane proteins may compete with binding to FUS aggregates.

  • A Conjugate of Aminoadamantane and Tetrahydro-γ-Carboline Inhibits Accumulation of Mutant α-Synuclein A53T in the Cellular Model of Proteinopathy

    by Marina V. Burak, Nadezhda E. Pukaeva, Victoria S. Kryshkova, Olga A. Kukharskaya, Maya R. Nazdracheva, Sergey A. Pukhov, Kirill A. Rachenkov, Alla V. Stavrovskaya, Vladimir P. Fisenko, Michail S. Kukharsky, et al.

    Pathological aggregation of α-synuclein is a key event in the development of synucleinopathies, such as Parkinson's disease and Lewy body dementia. Currently, no effective disease-modifying therapy is available, necessitating the search for new therapeutic agents. One promising strategy involves the use of low-molecular-weight compounds capable of inhibiting the formation of toxic protein aggregates. This study evaluates the anti-aggregation properties of EC3222x, a conjugate of pharmacophoric fragments of amantadine and a fluorinated derivative of tetrahydro-γ-carboline. α-Synucleinopathy was modeled in the SH-SY5Y neuroblastoma cell line by transfection with a plasmid vector encoding the mutant human α-synuclein A53T protein. EC3222x at a concentration of 1 µM reduced the number of cells with α-synuclein A53T aggregates. Its efficacy was comparable to that of SynuClean-D and Buntanetap, known inhibitors of α-synuclein aggregation. Treatment with EC3222x reduced both the level of diffusely distributed intracellular α-synuclein and the formation of mature fibrillar aggregates and large aggresomes. Importantly, EC3222x did not affect the accumulation of another aggregation-prone protein, TDP-43, in a similar cellular model, indicating its specificity for α-synuclein. These findings suggest that EC3222x may represent a promising candidate for the development of therapeutic agents targeting synucleinopathies.


  • Synthesis of Dicarbazoles and Carbazole-(2,3,4,9-tetrahydro-1H-carbazoles) Linked by Polyether Spacers

    by Alexey Yu. Aksinenko, Tatiana V. Goreva, Tatiana A. Epishina, Sergei O. Bachurin

    An effective approach was developed to the synthesis of dicarbazoles and carbazole–tetrahydrocarbazole hybrids tethered via di- or triethylene glycol spacers. These polyether spacers are susceptible to metabolic cleavage, enabling targeted delivery of the bioactive moiety to functionally important enzyme active sites.

  • Mitochondrial and Antioxidant Activity as the Basis of the Neuroprotective Effect of Potential Multitarget Drugs for the Treatment of Neurodegenerative Diseases

    by Elena Feofanovna Shevtsova, Alexey Yuryevich Aksinenko, Alla Vadimovna Stavrovskaya, Vladimir Petrovich Fisenko, Sergey Olegovich Bachurin

    Background: The mechanisms of neurodegeneration common to many neurodegenerative diseases include oxidative stress, mitochondrial dysfunctions, excitotoxicity, and others. Beyond the broad spectrum of strategies for developing neuroprotective agents that target stagespecific mechanisms in each neurodegenerative disease, considerable attention is also being given to approaches aimed at developing compounds that can effectively modulate general pathogenic mechanisms and enhance the overall resilience of neuronal cells to cell death induction. Objective: This review discusses some of the results on new multitarget multipharmacophore agents with neuroprotective effects, particularly through their influence on mitochondrial permeability transition and antioxidant properties. We conducted comprehensive online searches on PubMed to gather the latest data on multitarget multipharmacophore agents consisting of pre-defined pharmacophores that have already demonstrated neuroprotective properties. Results and Discussion: To create compounds with a desirable spectrum of biological activity, an approach based on the conjugation of specific structural fragments of pharmacologically active substances into a single molecular entity could be used. Core fragments of compounds that have already demonstrated neuroprotective properties due to mitochondrial and antioxidant mechanisms of action can be used as neuroactive scaffold Conclusion: The combination of several pharmacophores in one molecule may not only result in the mere addition of the useful properties of each component, but may also give rise to new types of biological activity. The examples of the appearance of new properties in such multipharmacophore compounds, not inherent in the reference agents, discussed in our review, may be considered a prospective approach for creating a novel generation of neuroprotective agents.


  • Open Access

    Artemisinin Stimulates Neuronal Cell Viability and Possess a Neuroprotective Effect In Vitro

    by Sergey A. Pukhov, Alexey V. Semakov, Nadezhda E. Pukaeva, Olga A. Kukharskaya, Tatyana V. Ivanova, Viktoriya S. Kryshkova, Sergey O. Bachurin, Michail S. Kukharsky

    Artemisinin is a sesquiterpene lactone derived from the plant Artemisia annua L., renowned for its antimalarial activity. Based on this compound, various derivatives and analogues have been obtained that exhibit diverse biological activities, including clinically approved drugs. Recently, increasing evidence has highlighted the neuroprotective potential of artemisinin. In this study, we evaluated the effects of artemisinin on the viability of neuronal-like cells, including primary hippocampal neuronal cultures. Artemisinin exhibited a stimulating effect on SH-SY5Y and HEK-293 cells and enhanced the survival of primary neurons at low concentrations (1 µM). In contrast, artemisinin derivatives, such as dihydroartemisinin, anhydrodihydroartemisinin, and artemisitene, did not display similar stimulatory activity, suggesting that the intact lactone ring is crucial for this property. Furthermore, artemisinin demonstrated a protective effect against endoplasmic reticulum (ER) stress induced by the proteasome inhibitor MG132 in SH-SY5Y cells. However, it did not exhibit protective activity against oxidative stress induced by sodium arsenite. Additionally, artemisinin effectively inhibited the aggregation of mutated TDP-43 protein in transfected SH-SY5Y cells. These findings suggest that artemisinin exerts neuroprotective effects by targeting key molecular pathways associated with neurodegeneration, offering potential therapeutic insights for related conditions.


  • Open Access

    Artemisinin Stimulates Neuronal Cell Viability and Possess a Neuroprotective Effect In Vitro

    by Sergey A. Pukhov, Alexey V. Semakov, Nadezhda E. Pukaeva, Olga A. Kukharskaya, Tatyana V. Ivanova, Victoria S. Kryshkova, Sergey O. Bachurin, Michail S. Kukharsky

    Artemisinin is a sesquiterpene lactone derived from the plant Artemisia annua L., renowned for its antimalarial activity. Based on this compound, various derivatives and analogues have been obtained that exhibit diverse biological activities, including clinically approved drugs. Recently, increasing evidence has highlighted the neuroprotective potential of artemisinin. In this study, we evaluated the effects of artemisinin on the viability of neuronal-like cells, including primary hippocampal neuronal cultures. Artemisinin exhibited a stimulating effect on SH-SY5Y and HEK-293 cells and enhanced the survival of primary neurons at low concentrations (1 µM). In contrast, artemisinin derivatives, such as dihydroartemisinin, anhydrodihydroartemisinin, and artemisitene, did not display similar stimulatory activity, suggesting that the intact lactone ring is crucial for this property. Furthermore, artemisinin demonstrated a protective effect against endoplasmic reticulum (ER) stress induced by the proteasome inhibitor MG132 in SH-SY5Y cells. However, it did not exhibit protective activity against oxidative stress induced by sodium arsenite. Additionally, artemisinin effectively inhibited the aggregation of mutated TDP-43 protein in transfected SH-SY5Y cells. These findings suggest that artemisinin exerts neuroprotective effects by targeting key molecular pathways associated with neurodegeneration, offering potential therapeutic insights for related conditions.

  • Biocatalysis: modern challenges and applications

    by S. D. Varfolomeev, V. Švedas, E. N. Efremenko, A. M. Egorov, M. G. Khrenova, V. I. Tishkov, D. L. Atroshenko, A. A. Pometun, S. S. Savin, N. N. Ugarova, et al.

    The review analyzes recent advances, challenges, and practical applications in the field of enzymes within the framework of chemical enzymology and enzyme engineering. The achievements in the fundamental understanding of molecular mechanisms of the catalytic cycle of enzymatic reactions made using quantum mechanics/molecular mechanics methods with supercomputer technologies and bioinformatic approaches are considered. The design of protein biocatalysts with new properties is a fundamentally significant methodology of the bioengineering approach to solving practical problems, which is demonstrated by a number of examples. The increasing role of biocatalysis in medicine and biomedical research is illustrated by addressing the problems of antibiotic synthesis and overcoming antibiotic resistance of bacteria, mechanisms of neurodegenerative diseases and development of drugs to treat Alzheimer's disease, biocatalytic processes of DNA repair and the role of mechanisms of functioning of heme peroxidases in the human body. The use of enzymes to degrade endogenous and exogenous toxicants has been greatly developed in recent decades. The advances and problems of using enzymes in therapy and drug delivery are analyzed. The fundamental role of enzymes in modern analysis and diagnosis is noted. The review considers a new trend in the development of bioanalytical methods using aptamers, multi-analysis systems on biochips, surface-enhanced Raman scattering systems, and bioelectroanalysis. The bibliography includes 460 references.


  • Open Access

    Combining Experimental and Computational Methods to Produce Conjugates of Anticholinesterase and Antioxidant Pharmacophores with Linker Chemistries Affecting Biological Activities Related to Treatment of Alzheimer’s Disease

    by Galina F. Makhaeva, Nadezhda V. Kovaleva, Elena V. Rudakova, Natalia P. Boltneva, Sofya V. Lushchekina, Tatiana Y. Astakhova, Elena N. Timokhina, Igor V. Serkov, Alexey N. Proshin, Yuliya V. Soldatova, et al.

    Effective therapeutics for Alzheimer’s disease (AD) are in great demand worldwide. In our previous work, we responded to this need by synthesizing novel drug candidates consisting of 4-amino-2,3-polymethylenequinolines conjugated with butylated hydroxytoluene via fixed-length alkylimine or alkylamine linkers (spacers) and studying their bioactivities pertaining to AD treatment. Here, we report significant extensions of these studies, including the use of variable-length spacers and more detailed biological characterizations. Conjugates were potent inhibitors of acetylcholinesterase (AChE, the most active was 17d IC50 15.1 ± 0.2 nM) and butyrylcholinesterase (BChE, the most active was 18d: IC50 5.96 ± 0.58 nM), with weak inhibition of off-target carboxylesterase. Conjugates with alkylamine spacers were more effective cholinesterase inhibitors than alkylimine analogs. Optimal inhibition for AChE was exhibited by cyclohexaquinoline and for BChE by cycloheptaquinoline. Increasing spacer length elevated the potency against both cholinesterases. Structure–activity relationships agreed with docking results. Mixed-type reversible AChE inhibition, dual docking to catalytic and peripheral anionic sites, and propidium iodide displacement suggested the potential of hybrids to block AChE-induced β-amyloid (Aβ) aggregation. Hybrids also exhibited the inhibition of Aβ self-aggregation in the thioflavin test; those with a hexaquinoline ring and C8 spacer were the most active. Conjugates demonstrated high antioxidant activity in ABTS and FRAP assays as well as the inhibition of luminol chemiluminescence and lipid peroxidation in mouse brain homogenates. Quantum-chemical calculations explained antioxidant results. Computed ADMET profiles indicated favorable blood–brain barrier permeability, suggesting the CNS activity potential. Thus, the conjugates could be considered promising multifunctional agents for the potential treatment of AD.


  • Исследование действия новых гибридных соединений на основе рилузола на клеточных моделях бокового амиотрофического склероза

    by Мария Александровна Лапшина, Сергей Олегович Бачурин, Владимир В. Григорьев, Алексей А. Устюгов, Алексей Ю. Аксиненко, Даниил А. Штейнберг, Григорий В. Малеев

    Рассмотрены некоторые возможности создания оригинальных конъюгатов препарата «Рилузол» с ключевыми структурными фрагментами фармакологически активных веществ с целью получения новых мультитаргетных соединений, способных одновременно действовать на несколько мишеней, участвующих в процессе развития бокового амиотрофического склероза. Проведена оценка действия рилузола, его производных (конъюгатов с другими фармакофорными фрагментами) и биоизостерных аналогов на высвобождение и обратный захват нейромедиатора глутамата нервными окончаниями на модели фракции синаптосом Р2 радиолигандным методом. Методом фиксации напряжения было также изучено действие всех синтезированных соединений на потенциал-управляемые быстрые Na+-токи нейронов головного мозга млекопитающих. Результаты лазерной конфокальной микроскопии позволили получить информацию о состоянии патогенного белка. Показано, что конъюгаты рилузола с тремя нейроактивными фармакофорными структурами, а именно, диметиламиноадамантаном, фенотиазином и тетрагидро-гамма-карболином, в 2 – 3 раза снижают патологическую агрегацию белка FUS (коэффициент агрегации в диапазоне 28 – 46 %). Биохимический анализ накоплений патологической изоформы белка FUS после дифференциального ультрацентрифугирования позволил сделать заключение о том, что соединение ТГ-2253 в наибольшей степени приводит к накоплению меченого белка в цитоплазматической, а не в цитоскелетной фракции.